Matthew R. Cooperberg, MD, MPH, presented “Pros and Cons of the ReIMAGINE Trial” during the 34th International Prostate Cancer Update on February 12, 2024, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Cooperberg, Matthew R. “Pros and Cons of the ReIMAGINE Trial.” February 2024. Accessed Nov 2024. https://grandroundsinurology.com/pros-and-cons-of-the-reimagine-trial/
Pros and Cons of the ReIMAGINE Trial – Summary
Matthew R. Cooperberg, MD, MPH, discusses the strengths and weaknesses of the Risk and Screening arms of the ongoing ReIMAGINE trial. He begins by describing the two arms of the study, ReIMAGINE Screening and ReIMAGINE Risk, and then focuses on the Screening arm, digging into the participant data.
Dr. Cooperberg addresses the sequence of screening tests in the ReIMAGINE trial, and reasserts the value of PSA as an initial screening marker, using supporting evidence from the ongoing STHLM3-MRI trial. He then briefly touches on ReIMAGINE Risk, noting that it will be useful as a biorepository in the future.
While ReIMAGINE Screening shows PSA with magnetic resonance imaging (MRI) is better than PSA alone, Dr. Cooperberg reiterates that, as an initial screening marker, PSA <1 (or 1.5) is tough to beat. Dr. Cooperberg explains that MRI is useful for helping to guide biopsy and is acceptable as a second screening tool. However, other markers are more effective and less expensive in the United States.
About The 34th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 34th iteration of the meeting occurred February 11-14, 2024 in Vail, Colorado. To view more educational presentations from IPCU 34, visit our collection page.
ABOUT THE AUTHOR
Matthew R. Cooperberg, MD, MPH, is Professor of Urology and Epidemiology & Biostatistics and Helen Diller Family Chair in Urology at the University of California, San Francisco. He earned an undergraduate degree in English from Dartmouth College in Hanover, New Hampshire, before pursuing his MD from the Yale School of Medicine in New Haven, Connecticut. Dr. Cooperberg also earned an MPH with a concentration in Health Policy from the Yale School of Epidemiology and Public Health. He joined the faculty at UCSF in 2009, and was named a professor there in 2018.
Dr. Cooperberg’s clinical interests include the diagnosis and management of genitourinary malignancies, as well as minimally-invasive techniques to treat benign and malignant diseases. His research focus is prostate cancer, and in this area he is particularly interested in health services, risk assessment and biomarkers, comparative effectiveness of treatments, and decision support and survivorship. He is also interested in care disparities and in looking at prostate cancer as an international disease.
Dr. Cooperberg has written over 400 peer-reviewed scientific articles and is an investigator on several ongoing federal grants. He has won the Young Investigator Award from the Prostate Cancer Foundation and the American Urological Association Gold Cystoscope Award, and was also named Young Urologist of the Year in 2015. He is a Fellow of the American College of Surgeons and a member of the American Urological Association and the Society for Urologic Oncology.
